Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Centre Hospitalier Universitaire De Nantes

Institut National De Recherche Pour L'agriculture L'alimentation Et L'envrionment

Grégory Bouchaud

Antoine Magnan

Cédric Le May

Bertrand Cariou

The present invention relates to the allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determined its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9−/−) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.

Methods and compositions for treating asthma and allergic diseases

Growing community of inventors

Nantes, France

Grégory Bouchaud